Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2021-06-03 Remuneration Information
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Grant of Restricted Share Units and Share Options
Remuneration Information Classification · 99% confidence The document explicitly discusses the granting of Restricted Share Units (RSUs) to a new board member and share options to a newly appointed Chief Scientific Officer, referencing approval from the Annual General Meeting. This content directly relates to insider transactions or changes in executive/director holdings and compensation structure. While it touches upon management appointments (MANG) and potentially remuneration (DEF 14A), the core subject is the issuance of equity awards (shares/options) to specific individuals. This aligns most closely with insider transactions or capital structure changes related to personnel. Since it details the grant of shares/options to executives/directors, it fits best under 'Transaction in Own Shares' (POS) if the focus is the issuance mechanism, or potentially 'Director's Dealing' (DIRS) if it were reporting a trade, but since it's an *award* of equity, 'POS' (Transaction in Own Shares, which covers issuance) is a strong candidate, or perhaps 'SHA' (Share Issue/Capital Change). However, given the context of executive compensation/awards, and the specific mention of options and RSUs being granted, this is a form of capital change related to employee incentives. Reviewing the definitions, 'POS' (Transaction in Own Shares) covers the company buying back or selling its own shares. 'SHA' covers new share issues. Since this is an award of equity instruments (RSUs/Options) to employees/directors, it is a form of share issuance/capital change. Given the specific nature of equity awards to insiders, 'POS' (Transaction in Own Shares) is often used for repurchases, but can sometimes cover issuances related to incentive plans. 'SHA' (Share Issue/Capital Change) is broader. Since the document is short and announces the grant, and it is not a full remuneration report (DEF 14A) or a general capital update (CAP), the most specific fit for the *issuance* of shares/options as compensation is often captured under capital changes related to employee plans. However, if we strictly follow the definitions, this is an issuance of shares/options. Let's re-evaluate: It is not a Director's Dealing (DIRS) as that is reporting a trade. It is not a full remuneration report (DEF 14A). It is a specific capital change event related to employee compensation. 'SHA' (Share Issue/Capital Change) is the most appropriate general category for the issuance of new shares/options, even if tied to compensation. The document is short and announces the grant, but it is not merely announcing the *publication* of a report, so RPA/RNS is not the primary choice. I will classify this as a Share Issue/Capital Change (SHA).
2021-06-03 English
Vaccibody to present at Jefferies Virtual Healthcare Conference (June 1-4, 2021)
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the CEO and Chief Innovation & Strategy Officer of Vaccibody AS will be presenting at the Jefferies Virtual Healthcare Conference on June 2, 2021. This is an announcement about an upcoming investor event, not the release of formal financial results (ER), a full report (10-K/IR), or a transcript of a call (CT). It is an announcement intended for investors regarding company activities and strategy presentation. While it is an announcement, it doesn't fit the specific definition of 'Report Publication Announcement' (RPA) which usually concerns the release of a formal report. It is best classified as a general Investor Presentation announcement or a Regulatory Filing (RNS) if no better fit exists. Given the context of presenting company information to investors, it is most closely related to investor relations activities. Since there is no specific code for 'Conference Presentation Announcement', and it is not the presentation itself (IP), the most appropriate general category for an announcement of this nature that doesn't fit the specific financial report types is the general Regulatory Filings category (RNS). However, if we consider the content is about an upcoming presentation, it is an announcement of an investor event. Given the options, RNS is the safest fallback, but let's re-evaluate against 'IP' (Investor Presentation). Since this is an *announcement* of a presentation, not the presentation slides themselves, it is not 'IP'. It is a general corporate update. Therefore, RNS is the most suitable fallback.
2021-05-31 English
Vaccibody to present at Jefferies Virtual Healthcare Conference (June 1-4, 2021)
Regulatory Filings Classification · 100% confidence The document is a short press release announcing that Vaccibody's CEO and CSO will be presenting at the Jefferies Virtual Healthcare Conference on a specific date (June 2, 2021). It provides details about the presentation time and where the presentation materials will be available. This type of announcement, which publicizes participation in an external industry event (like a conference presentation), does not fit neatly into the specific financial reporting categories (10-K, IR, ER, etc.). Since it is a general corporate announcement regarding investor relations activities, and it is not a transcript (CT) or a formal investor presentation document itself (IP), the most appropriate fallback category is Regulatory Filings (RNS), as it serves as a general regulatory/investor communication.
2021-05-31 English
Share capital increase from exercise of warrants
Share Issue/Capital Change Classification · 98% confidence The document explicitly discusses a 'Share capital increase from exercise of warrants'. This action directly relates to changes in the company's share structure and capital base. This aligns perfectly with the definition of 'Share Issue/Capital Change' (Code: SHA), which covers new share issues and capital structure changes. Although it involves insiders exercising warrants, the primary focus and announcement are about the resulting capital increase, making SHA a better fit than DIRS or CAP.
2021-05-12 English
Vaccibody AS - Quarterly report Q1 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled '1st Quarter 2021 Report' and contains comprehensive financial statements, including an income statement, statement of financial position, and cash flow analysis for the period ending March 31, 2021. It provides detailed management commentary on R&D activities, financial performance, and outlook. As it contains substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2021
2021-05-12 English
Vaccibody AS - Quarterly report Q1 2021
Report Publication Announcement Classification · 99% confidence The document is titled 'Vaccibody AS - Quarterly report Q1 2021' and announces the first quarter 2021 results. However, the text itself does not contain the detailed financial statements or management discussion typical of a full Interim/Quarterly Report (IR). Instead, it explicitly states: 'The first quarter 2021 report will be available at [URL]'. Given the short length (2497 characters) and the clear indication that the actual report is published elsewhere, this document fits the definition of a Report Publication Announcement (RPA), which announces the release or availability of a report.
2021-05-12 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.